CG Oncology (CGON) Equity Ratio (2023 - 2025)
CG Oncology (CGON) has disclosed Equity Ratio for 3 consecutive years, with 0.95 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Ratio fell 2.15% year-over-year to 0.95, compared with a TTM value of 0.95 through Dec 2025, down 2.15%, and an annual FY2025 reading of 0.95, down 2.15% over the prior year.
- Equity Ratio was 0.95 for Q4 2025 at CG Oncology, up from 0.94 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.98 in Q1 2024 and bottomed at 0.62 in Q4 2023.
- Average Equity Ratio over 3 years is 0.79, with a median of 0.97 recorded in 2025.
- The sharpest move saw Equity Ratio skyrocketed 257.31% in 2024, then fell 3.04% in 2025.
- Year by year, Equity Ratio stood at 0.62 in 2023, then surged by 257.31% to 0.97 in 2024, then decreased by 2.15% to 0.95 in 2025.
- Business Quant data shows Equity Ratio for CGON at 0.95 in Q4 2025, 0.94 in Q3 2025, and 0.96 in Q2 2025.